<h1>John Round</h1>

<h2>Overview</h2>

<p>Highly skilled professional with expertise in the field of biotech diligence. Passionate about leveraging data-driven insights to drive innovation and strategic decision-making. Recognized for delivering impactful research and analysis that informs critical business decisions.</p>

<h2>Education</h2>

<ul>
<li>Ph.D. in Biotechnology, University of Cambridge, UK</li>
<li>M.S. in Molecular Biology, University of Oxford, UK</li>
<li>B.S. in Biochemistry, University of Edinburgh, UK</li>
</ul>

<h2>Research Interests</h2>

<ul>
<li>Biotech industry analysis and due diligence</li>
<li>Emerging trends and technologies in the life sciences</li>
<li>Data-driven decision-making for strategic investments</li>
<li>Translational research and commercialization of novel therapies</li>
</ul>

<h2>Publications</h2>

<ul>
<li>"Evaluating the Potential of CRISPR-Cas9 in Rare Disease Treatment" (Journal of Biotechnology, 2021)</li>
<li>"Navigating the Biotech Landscape: A Comprehensive Diligence Framework" (Nature Biotechnology, 2020)</li>
<li>"Optimizing Biotech Venture Capital Portfolios" (Trends in Biotechnology, 2019)</li>
</ul>

<h2>Awards</h2>

<ul>
<li>Recipient, Biotechnology Innovator Award, 2022</li>
<li>Finalist, Biotech Diligence Excellence Award, 2021</li>
<li>Young Investigator Award, International Biotechnology Conference, 2020</li>
</ul>
